CIK 0001832038
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Invivyd, Inc.
Sign in to watch- Ticker
- IVVD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851403134
- Phone
- +1 781-819-0080
- Business address
- 205 CHURCH STREET, NEW HAVEN, CT
- Former names
- Adagio Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-18 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −18,425 | $0.84 | $16K | 168,937 |
| 2026-08-17 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −22,355 | $0.72 | $16K | 187,362 |
| 2026-08-15 | Duke William E. Chief Financial Officer | Exercise or conversion 10b5-1 | +102,000 | 209,717 | ||
| 2026-08-15 | Duke William E. Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −102,000 | 0 | ||
| 2026-02-18 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −20,964 | $1.58 | $33K | 107,717 |
| 2026-02-17 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −19,663 | $1.54 | $30K | 128,681 |
| 2026-02-15 | Duke William E. Chief Financial Officer | Exercise or conversion 10b5-1 | +99,000 | 148,344 | ||
| 2026-02-15 | Duke William E. Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −99,000 | 102,000 | ||
| 2026-01-29 | Duke William E. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +625,000 | 625,000 | ||
| 2025-08-19 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −29,643 | $0.57 | $17K | 49,344 |
| 2025-08-18 | Duke William E. Chief Financial Officer | Sale 10b5-1 | −20,013 | $0.65 | $13K | 78,987 |
| 2025-08-15 | Duke William E. Chief Financial Officer | Exercise or conversion 10b5-1 | +99,000 | 99,000 | ||
| 2025-08-15 | Duke William E. Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −99,000 | 201,000 | ||
| 2025-02-15 | Duke William E. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +950,000 | 950,000 | ||
| 2025-02-15 | Duke William E. Chief Financial Officer | Grant or award · Restricted Stock Units | +300,000 | 300,000 | ||
| 2023-12-18 | Duke William E. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-09-01 | Duke William E. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +750,000 | 750,000 |
Page 1 of 1 · 17 trades